Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review

Bulletin Express

09/11

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.

The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.

The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.

Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1182293455"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182293455\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182293455?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182293455","market":"us","top_or_hot":-1,"title":"Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.</p>\n<p>The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.</p>\n<p>The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.</p>\n<p>Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-09-11 16:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.</p>\n<p>The fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.</p>\n<p>The company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.</p>\n<p>Chairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森製藥","start_time":0,"source_url":"","article_id":"1182293455","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182293455","pubTimestamp":1789116394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森制药治疗小细胞肺癌的Risvutatug Rezetecan进入NMPA优先审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) reported that the National Medical Products Administration (NMPA) placed risvutatug rezetecan for injection (HS-20093) under its Priority Review and Approval Procedure on 21 August 2026.\nThe fast-track designation is based on positive pivotal Phase III ARTEMIS-008 data for patients with small-cell lung cancer (SCLC) whose disease progressed after prior platinum-based chemotherapy.\nThe company disclosed the development in a voluntary announcement dated 11 September 2026. No additional financial terms or timelines were provided.\nChairlady Zhong Huijuan signed the announcement on behalf of the board, which currently comprises three executive directors and four independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}